Immunoprevention and immunotherapy of cancer in ageing.
Over the last few years there has been a growing interest in geriatric oncology, mainly because of the evidence that advanced age is the greatest risk factor for the development of cancer and that, since the elderly population is rapidly expanding, so too will the number of cancer patients. This forecast necessitates the development of new and more specific strategies for the prevention and cure of cancer in the elderly and as a result an ever-increasing need for oncologists, geriatricians and researchers to work closely together. The increased incidence of cancer in elderly people has been related to the age-associated changes occurring in the immune system, the so-called immunosenescence. This phenomenon is best characterised by a remodelling of the immune system, which appears early on and progresses throughout a person's life and mainly involves a decrease in cellular functions. This review aims to provide a rationale for the development of specific immunotherapeutic and immunopreventive regimens for the elderly. We also include a discussion on the influence that immunosenescence has on the growth of tumours and the effectiveness of immunogene therapy and cancer vaccination following a brief analysis of the age-related alterations of the cell populations involved in antitumour immunity.
Provinciali
Mauro
M
INRCA Research Department, Laboratory of Tumour Immunology, Via Birarelli 8, 60121, Ancona, Italy. m.provinciali@inrca.it
Smorlesi
Arianna
A
D000375:Aging; D000818:Animals; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy; D009369:Neoplasms / Q000517:prevention & control*